Express Scripts launches initiative to reduce cost of inflammatory drugs

9 September 2016

America’s largest pharmacy benefits management company has launched an initiative aimed at controlling costs and improving care for people with inflammatory conditions like rheumatoid arthritis, psoriasis and Crohn's Disease.

Express Scripts said the Inflammatory Conditions Care Value Program (SM) was intended to reduce spending on expensive prescription drugs by managing a formulary category around each individual inflammatory condition and thereby increasing competition among manufacturers.

Drugs to treat inflammation, such as AbbVie's (NYSE: ABBV) Humira (adalimumab) and Amgen's (Nasdaq: AMGN) Enbrel (etanercept), are among the top selling US drugs and have more than doubled in price in the past five years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK